* Transgene: UC Davis to conduct phase 2 trial of the
combination of TG4010 with Opdivo (Nivolumab) for 2nd line
treatment of metastatic non-small cell lung cancer (NSCLC)
The post BRIEF-Transgene says UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo appeared first on NASDAQ.